News
Opinion
Sports
Business
Community
entertainment
Schools
News
Announcements
Classifieds
Place Ad
Advertising
Contact Us
Archives
Search

Turkey Creek Medical Center pioneers medical study


Farragut’s Turkey Creek Medical Center — formerly Mercy Medical Center West — enrolled the first U.S. patient in a global EXCEL trial.

EXCEL is a global, prospective, multi-center, randomized trial to assess the safety and efficacy of the XIENCE PRIME or XIENCE V Everolimus Eluting Coronary Stent Systems, compared to coronary artery bypass grafting, or surgery, in select patients with unprotected left main coronary artery disease.

The first U.S. patient, a native of Seymour, was enrolled into the EXCEL trial at Turkey Creek Medical Center by Michael L. Maggart, M.D., cardiothoracic surgeon, and Malcolm T. Foster, M.D., interventional cardiologist.

Left main disease is a high-risk subset of coronary artery disease involving blockage of the left main coronary artery, which branches off the aorta to provide blood flow to the left ventricle of the heart. Surgery traditionally has been the standard treatment for left main disease, with coronary stenting reserved only for patients at high risk for surgery and who are “protected” by a previous bypass graft to at least one of the two major coronary arteries that branch off the left main artery.


The EXCEL trial will evaluate “unprotected” patients with left main disease who have not received grafts to these arteries to determine whether coronary stenting can be an alternative to bypass surgery in these patients.

The trial is being led by a multi-disciplinary team of physician specialists representing both surgeons and cardiologists, and will enroll more than 2,600 patients at up to 165 medical centers in 18 countries.

Select patients who have unprotected left main disease will be randomized to receive a drug eluting stent (XIENCE PRIME or XIENCE V) or CABG.

The primary endpoint of the study is the composite measure of all-cause mortality, myocardial infarction, or stroke at a median follow-up duration of three years, with all randomized patients having reached a minimum of two years’ follow-up.

Abbott Vascular is a global leader in cardiac and vascular care with market-leading products and an industry-leading pipeline. Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products.

 

News | Opinion | Sports | Business | Community | Schools | Obituaries | Announcements
Classifieds | Place Ad | Advertising | Contact Us | Archives | Search

© 2004-2014 farragutpress